SCHEMBL27037342

SCHEMBL27037342

COc1ccc2cc(OS(=O)(=O)C(F)(F)F)nn2c1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 1/20 0.34
▸ CA2 P00918 1/20 0.34
▸ PTGS2 P35354 5/20 0.33
▸ PTGS1 P23219 3/20 0.33
▸ DRD2 P14416 4/20 0.32
▸ DRD3 P35462 4/20 0.32
▸ HTR1D P28221 2/20 0.32
▸ HSD11B1 P28845 1/20 0.32
▸ CXCR2 P25025 2/20 0.32
▸ CHRM1 P11229 4/20 0.32
▸ DRD4 P21917 3/20 0.32
▸ GAA P10253 1/20 0.32
▸ KDM4E B2RXH2 1/20 0.32
▸ USP2 O75604 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ TP53 P04637 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27037831 0.82 PDE4A (0.33) CA1CA2DRD2DRD3DRD4
SCHEMBL27038587 0.82 PTGS2 (0.32) CA1CA2PTGS2PTGS1DRD2
SCHEMBL29488940 0.80 NOTUM (0.36) GAAKDM4EALDH1A1HPGDKMT2A
SCHEMBL23706009 0.75 TP53 (0.40) DRD2DRD3DRD4KDM4EALDH1A1
SCHEMBL10263024 0.75 KDM4E (0.35) CXCR2KDM4EALDH1A1KMT2A
SCHEMBL27037708 0.73 PKM (0.39) CA1CA2ALDH1A1KMT2ASMN1; SMN2
SCHEMBL27038244 0.72 APP (0.41) CA1CA2PTGS2PTGS1HSD11B1
SCHEMBL1997269 0.71 CA1 (0.57) CA1CA2HSD11B1CXCR2GAA
SCHEMBL27147717 0.70 FFAR2 (0.36) —
SCHEMBL27038176 0.70 FFAR2 (0.36) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4539840-A1 KINASE MODULATORS AND METHODS OF USE THEREOF Neuron23, Inc. (US) 2025-04-23 — — EP disclosed
CN-119730846-A Kinase modulators and methods of use thereof 神经元23公司 2025-03-28 — — CN disclosed
WO-2023244788-A9 KINASE MODULATORS AND METHODS OF USE THEREOF NEURON23, INC. (US) 2024-09-12 — — WO disclosed
US-20240025906-A1 KINASE MODULATORS AND METHODS OF USE THEREOF SUNDANCE BIOSCIENCES, INC. 2024-01-25 — — US disclosed
US-20240025906-A1 KINASE MODULATORS AND METHODS OF USE THEREOF SUNDANCE BIOSCIENCES, INC. 2024-01-25 — — US disclosed
US-20240025906-A1 KINASE MODULATORS AND METHODS OF USE THEREOF SUNDANCE BIOSCIENCES, INC. 2024-01-25 — — US disclosed
WO-2023244788-A1 KINASE MODULATORS AND METHODS OF USE THEREOF NEURON23, INC. (US) 2023-12-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240025906-A1 KINASE MODULATORS AND METHODS OF USE THEREOF TYK2, JAK1, JAK3 CA1 4843/4885CA2 4086/4885PTGS2 1318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback